Tarsus Pharmaceuticals reported a third-quarter net loss of $668.3 million, or $14.40 per share, driven by a $632.2 million non-cash charge for acquired in-process research and development related to the acquisitions of iRenix Medical and Alkeus Pharmaceuticals. Excluding this item, product sales grew 64% year-over-year to $194.6 million as XDEMVY surpassed one million bottles dispensed and $1 billion in cumulative net sales. The company appointed Neera Clase as Chief Commercial Officer and provided updates on its pipeline, including Phase 2 trials for TP-04 and TP-05 with top-line data expected in early 2027. Tarsus Pharmaceuticals operates in the pharmaceutical industry, developing treatments for eye care diseases such as Demodex blepharitis.
